Market Overview

Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017

Share:

-- Presentations include 6-month data for treatment of chronic knee pain
associated with osteoarthritis; 6-month and 12-week data for treatment
of Morton's neuroma --

Centrexion Therapeutics, a company focused on advancing the treatment
of chronic pain with one of the largest exclusively pain-focused
pipelines of non-opioid therapies in active development, today announced
it will present three studies of CNTX-4975 at the American College of
Rheumatology and the Association of Rheumatology Health Professionals'
(ACR/ARHP) 2017 Annual Meeting taking place from November 3 – 8 at the
San Diego Convention Center in San Diego, California. The presentations
include 6-month data from the Phase 2b TRIUMPH study assessing the
efficacy and safety of CNTX-4975 for the treatment of moderate to severe
chronic knee pain associated with osteoarthritis as well as 12-week and
6-month data from a study of CNTX-4975 for the treatment of
intermetatarsal neuroma (Morton's neuroma).

Full abstracts are available at http://acrabstracts.org.
Details of the poster presentations are listed below.

Abstract Title (#1191): Efficacy and Safety of Cntx-4975 in
Subjects with Moderate to Severe Osteoarthritis Knee Pain: 24-Week,
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Session
Title:
Osteoarthritis – Clinical Aspects Poster I: Clinical Trials
and Interventions
Session Type: ACR Poster Session B
Presentation
Time
: 9:00-11:00 a.m. PT, Monday, November 6
Location:
Poster Hall

Abstract Title (#2225): Cntx-4975 (Trans-Capsaicin) Injection
Provides Clinically Meaningful Pain Reduction in Subjects with Painful
Intermetatarsal Neuroma (Morton's Neuroma): An Open-Label,
Ascending-Dose Study
Session Title: Pain – Basic and
Clinical Aspects Poster
Session Type: ACR Poster Session C
Presentation
Time
: 9:00-11:00 a.m. PT, Tuesday, November 7
Location:
Poster Hall

Abstract Title (#2226): Cntx-4975 (Trans-Capsaicin) Injection
Provides Clinically Meaningful Pain Reduction in Subjects with Painful
Intermetatarsal Neuroma (Morton's Neuroma): A Randomized, Double-Blind,
Placebo-Controlled, Dose-Ranging Study
Session Title: Pain –
Basic and Clinical Aspects Poster
Session Type: ACR Poster
Session C
Presentation Time: 9:00-11:00 a.m. PT, Tuesday,
November 7
Location: Poster Hall

About CNTX-4975

CNTX-4975 is based on Centrexion's proprietary STRATI™ technology (Synthetic
TRans cApsaicin ulTra-pure Injection), a
highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine
traditionally derived from the chili plant). CNTX-4975 is designed to be
injected directly into the site of pain to provide rapid onset, large
reduction and long duration of relief from moderate to severe pain
without affecting touch sensibility or position sense.

CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1)
to rapidly inactivate only the local pain fibers transmitting signals to
the brain. With a short half-life, STRATI® is cleared from the body
within 24 hours. This approach provides pain relief that can last for
months until the ends of the local pain fibers regenerate, while leaving
the rest of the nerve fiber functioning as normal, and without the risks
of toxicities of NSAIDs and injected steroids or the side effects,
including abuse and addiction, associated with opioid treatments.

About Centrexion Therapeutics

Centrexion Therapeutics, Corp. is focused on advancing the treatment
of chronic moderate to severe pain with one of the largest exclusively
pain-focused pipelines of non-opioid, non-addictive therapies in active
development. Centrexion Therapeutics recognizes the needs of over a
quarter of a billion patients living with chronic pain worldwide, and
aims to develop new, safer and more effective therapies that overcome
the limitations and challenges associated with current pain treatments.
Founded by world-renowned leaders in drug development and well-funded by
key investors, Centrexion Therapeutics is building a pain treatment
powerhouse to address the substantial and growing global chronic pain
epidemic. Centrexion Therapeutics has recently relocated from Baltimore,
Md. to Boston, Mass.

For more information about Centrexion, visit http://www.centrexion.com.

View Comments and Join the Discussion!